Eugene Lin, MD, MS, FASN

Associate Professor of Medicine and Health Policy and Management

Image of Eugene Lin, MD, MS, FASN
Is this your profile? Click to edit

Overview

Eugene Lin, MD, MS, is a nephrologist and health services researcher with a focus on economic policies pertaining to kidney disease. He is a nationally recognized expert on the impact of public policy and federal regulation on kidney care, the provision of dialysis in public and private insurance markets, and transitions of care for patients with kidney disease. He is an NIH funded investigator, and his work has been published in leading health policy and medical journals, including JAMA, Health Affairs, and JAMA Internal Medicine.

In addition to his academic roles at USC, he currently serves on the National Kidney Foundation’s Scientific Advisory Board and the American Society of Nephrology’s Transplant Policy Committee. He has also participated as a key stakeholder in multiple Technical Expert Panels for the Centers for Medicare and Medicaid Services.

Dr. Lin completed a postdoctoral fellowship in nephrology at the Stanford School of Medicine and completed his Internal Medicine residency at the Hospital of the University of Pennsylvania.

Education and Training

  • USC, Los Angeles, CA — Visiting Scholar — 2018
  • Stanford University School of Medicine, Palo Alto, CA — Fellow — 2018 — Nephrology
  • Stanford University, Stanford, CA — M.S. — 2017 — Health Services Research
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Resident — 2014 — Internal Medicine
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Intern — 2012
  • Baylor College of Medicine, Houston, TX — M.D. — 2011 — Medicine
  • Stanford University, Stanford, CA — B.S. — 2006 — Biology, minor in Mathematics

Research Funding

  • Elucidating the Mechanisms of Racial and Ethnic Disparities in Dialysis Quality
    NIH · R01DK137223 · Sep 1, 2023 – Jun 30, 2028 · Role: Principal Investigator
  • Comparing Dialysis Provision and Outcomes Between Medicare Advantage and Fee-for-Service Medicare
    NIH · R03DK131239 · Jul 1, 2022 – Jun 30, 2024 · Role: Principal Investigator
  • The Impact of Medicare Advantage on Patients with End-Stage Kidney Disease
    American Society of Nephrology (KidneyCure) · Jul 1, 2021 – Jun 30, 2023 · Role: Principal Investigator
  • Investigating the Economic and SocialDeterminants of Home Dialysis Drop-Out
    NIH · K08DK118213 · Aug 15, 2018 – May 31, 2024 · Role: Principal Investigator
  • Investigating the Appropriateness of 30-Day Rehospitalizations in Dialysis Patients
    NIH · F32DK107123 · Jul 20, 2015 – Jul 19, 2018 · Role: Principal Investigator

Research Keywords

  • Dialysis Delivery
  • Multidisciplinary Care in Kidney Disease
  • Value-Based Purchasing
  • Medicare Payment Policy
  • Decision Analysis

Publications

  • Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 2011 May; 25(5):1653-63.. View in PubMed
  • Bacteria in the treatment of cancer. Curr Opin Mol Ther. 2004 Dec; 6(6):629-39.. View in PubMed
  • Oncolytic viral therapies. Cancer Gene Ther. 2004 Oct; 11(10):643-64.. View in PubMed